It has been about a month since the last earnings report for Editas Medicine (EDIT). Shares have added about 40% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Editas due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended downward during the past month.
VGM Scores
At this time, Editas has an average Growth Score of C, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions has been net zero. Notably, Editas has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Editas belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Mirum Pharmaceuticals, Inc. (MIRM), has gained 8.2% over the past month. More than a month has passed since the company reported results for the quarter ended March 2025.
Mirum Pharmaceuticals reported revenues of $111.58 million in the last reported quarter, representing a year-over-year change of +61.2%. EPS of -$0.30 for the same period compares with -$0.54 a year ago.
Mirum Pharmaceuticals is expected to post a loss of $0.32 per share for the current quarter, representing a year-over-year change of +38.5%. Over the last 30 days, the Zacks Consensus Estimate has changed +3.8%.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Mirum Pharmaceuticals. Also, the stock has a VGM Score of B.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Editas Medicine, Inc. (EDIT): Free Stock Analysis Report Mirum Pharmaceuticals, Inc. (MIRM): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
